Dato-DXd

Clinical insights on datopotamab deruxtecan (Dato-DXd) in non–small cell lung cancer, including efficacy, safety, and sequencing considerations. It highlights evolving evidence to inform integration of this antibody-drug conjugate into treatment pathways.

Ep. 5: CNS Activity and Sequencing Strategies for Datopotamab Deruxtecan in EGFR-Mutant NSCLC

Aaron Lisberg, MD, Sarah Sunshine, MD, Blanca Ledezma, NP, Rahul Gosain, MD, MBA, Rohit Gosain, MD

Ep. 4: Datopotamab Deruxtecan in EGFR-Mutated NSCLC: Community-Based Monitoring and Toxicity Management

Aaron Lisberg, MD, Sarah Sunshine, MD, Blanca Ledezma, NP, Rahul Gosain, MD, MBA, Rohit Gosain, MD

EP. 3: Monitoring, Dosing, and Rechallenge Strategies With Datopotamab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

Aaron Lisberg, MD, Sarah Sunshine, MD, Blanca Ledezma, NP, Rahul Gosain, MD, MBA, Rohit Gosain, MD

Ep. 2: Managing Ocular Toxicity, Mucositis, and ILD With Datopotamab Deruxtecan in EGFR-Mutated NSCLC

Aaron Lisberg, MD, Sarah Sunshine, MD, Blanca Ledezma, NP, Rahul Gosain, MD, MBA, Rohit Gosain, MD

Ep. 1: Efficacy, Safety, and Management of Dato-DXd in EGFR-Mutated Lung Cancer

Aaron Lisberg, MD, Sarah Sunshine, MD, Blanca Ledezma, NP, Rahul Gosain, MD, MBA, Rohit Gosain, MD

Multidisciplinary Strategies for Dato-DXd in Pretreated EGFR-Mutated Advanced NSCLC (Full Video)

Aaron Lisberg, MD, Sarah Sunshine, MD, Blanca Ledezma, NP, Rahul Gosain, MD, MBA, Rohit Gosain, MD